New Drug Combo Shows Promise Against Aggressive Thyroid Cancer
Lenvatinib plus pembrolizumab combination therapy demonstrated 36% response rate in patients with deadly anaplastic thyroid cancer.
Summary
A new combination therapy shows promise against one of the deadliest forms of thyroid cancer. Researchers studied 36 patients with anaplastic thyroid carcinoma who received lenvatinib plus pembrolizumab as first-line treatment. The combination achieved a 36% response rate, with some patients experiencing complete tumor disappearance. Median survival was 7.7 months, and progression-free survival was 6.2 months. While these cancers typically have extremely poor outcomes, this real-world study confirms earlier clinical trial results showing meaningful responses. The treatment was generally well-tolerated, though some patients experienced immune-related side effects requiring treatment discontinuation.
Detailed Summary
Anaplastic thyroid carcinoma represents one of the most aggressive cancers known, with historically dismal survival rates. This real-world study provides encouraging evidence that a combination immunotherapy approach may offer new hope for patients facing this devastating diagnosis.
Researchers analyzed 36 patients with metastatic anaplastic thyroid cancer lacking BRAF mutations who received lenvatinib (a targeted therapy) plus pembrolizumab (an immunotherapy drug) outside of clinical trials. All patients had advanced disease with distant metastases, and nearly half showed signs of local invasion into critical structures like the trachea and esophagus.
The combination therapy achieved a 36% overall response rate, including complete tumor disappearance in 9% of patients and partial responses in 28%. Median overall survival reached 7.7 months, with progression-free survival of 6.2 months. For patients who responded, the median duration of response was 16 months, suggesting durable benefit in some cases.
From a longevity perspective, this research highlights how precision medicine approaches combining targeted therapy with immunotherapy can transform outcomes even in the most challenging cancers. The study validates that real-world results match clinical trial findings, supporting broader access to this treatment combination.
Important limitations include the single-center design and relatively small patient population. Additionally, while these survival improvements are meaningful for this aggressive cancer type, absolute survival times remain limited, emphasizing the continued need for earlier detection strategies and novel therapeutic approaches.
Key Findings
- Combination therapy achieved 36% response rate with 9% complete responses in aggressive thyroid cancer
- Median overall survival of 7.7 months represents improvement over historical outcomes
- Treatment responses lasted median 16 months when achieved, showing durable benefit
- Real-world results confirmed earlier clinical trial findings for broader patient access
Methodology
Retrospective single-center study of 36 patients with metastatic BRAF wild-type anaplastic thyroid carcinoma treated with first-line lenvatinib plus pembrolizumab between 2016-2024. Median follow-up was 39.5 months with evaluation of response rates, survival outcomes, and safety profiles.
Study Limitations
Single-center retrospective design limits generalizability across different healthcare systems. Small sample size of 36 patients may not capture full spectrum of treatment responses. Survival improvements, while meaningful, remain modest in absolute terms for this aggressive cancer type.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.